

# Oklahoma Health Care Authority

Drug Utilization Review Board  
(DUR Board)

Meeting – October 9, 2019 @ 4:00pm

Oklahoma Health Care Authority  
4345 N. Lincoln Blvd.  
Oklahoma City, Oklahoma 73105

---

## AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

**1. Call to Order**

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

**2. Public Comment Forum – See Appendix A**

- A. Acknowledgment of Speakers for Public Comment
- B. Changes to Public Comment Procedure

Items to be presented by Dr. Muchmore, Chairman:

**3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix B**

- A. September 11, 2019 DUR Minutes – Vote
- B. September 11, 2019 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**4. Update on Medication Coverage Authorization Unit/Fall 2019 Pipeline Update – See Appendix C**

- A. Pharmacy Helpdesk Activity for September 2019
- B. Medication Coverage Activity for September 2019
- C. Fall 2019 Pipeline Update

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**5. Action Item – Vote to Prior Authorize Ezallor™ Sprinkle (Rosuvastatin Capsule) and Welchol® (Colesevelam Chewable Bar) – See Appendix D**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Sorilux® (Calcipotriene 0.005% Foam) – See Appendix E**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Herzuma® (Trastuzumab-pkrb), Kanjinti™ (Trastuzumab-anns), Ontruzant® (Trastuzumab-dttb), Piqray® (Alpelisib), Talzenna® (Talazoparib), and Trazimera™ (Trastuzumab-qyyp) – See Appendix F**

- A. Introduction
- B. Product Summaries
- C. Recommendations

Items to be presented by Dr. Schmidt, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Nubeqa® (Darolutamide) – See Appendix G**

- A. Introduction
- B. Nubeqa® (Darolutamide) Product Summary
- C. Recommendations

Items to be presented by Dr. Schmidt, Dr. Muchmore, Chairman:

**9. Annual Review of Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Medications – See Appendix H**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of ALL/CML Medications
- D. Prior Authorization of ALL/CML Medications
- E. Market News and Updates
- F. Recommendations
- G. Utilization Details of ALL/CML Medications

Items to be presented by Dr. Schmidt, Dr. Muchmore, Chairman:

**10. 30-Day Notice to Prior Authorize Turalio™ (Pexidartinib) – See Appendix I**

- A. Introduction
- B. Turalio™ (Pexidartinib) Product Summary
- C. Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**11. Action Item – Annual Review of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators – See Appendix J**

- A. Current Prior Authorization Criteria
- B. Utilization of CFTR Modulators
- C. Prior Authorization of CFTR Modulators
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of CFTR Modulators

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**12. Annual Review of Amyloidosis Medications and 30-Day Notice to Prior Authorize Vyndaqel® (Tafamidis Meglumine) and Vyndamax™ (Tafamidis) – See Appendix K**

- A. Current Prior Authorization Criteria
- B. Utilization of Amyloidosis Medications
- C. Prior Authorization of Amyloidosis Medications
- D. Market News and Updates
- E. Vyndaqel® (Tafamidis Meglumine) and Vyndamax™ (Tafamidis) Product Summaries
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**13. Annual Review of Various Systemic Antibiotics and 30-Day Notice to Prior Authorize Recarbrio™ (Imipenem/Cilastatin/Relebactam) and Xenleta™ (Lefamulin) – See Appendix L**

- A. Current Prior Authorization Criteria
- B. Utilization of Various Systemic Antibiotics
- C. Prior Authorization of Various Systemic Antibiotics
- D. Market News and Updates
- E. Recarbrio™ (Imipenem/Cilastatin/Relebactam) Product Summary
- F. Xenleta™ (Lefamulin) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Various Systemic Antibiotics

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**14. Annual Review of Hepatitis C Medications and 30-Day Notice to Prior Authorize Harvoni® (Ledipasvir/Sofosbuvir Oral Pellets) and Sovaldi® (Sofosbuvir Oral Pellets) – See Appendix M**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Trends of Hepatitis C Medication Utilization
- D. Hepatitis C Summary Statistics for Treated Members
- E. Utilization of Hepatitis C Medications
- F. Prior Authorization of Hepatitis C Medications

- G. Market News and Updates
- H. Regimen Comparison
- I. College of Pharmacy Recommendations
- J. Utilization Details of Hepatitis C Medications

Non-Presentation; Questions Only:

**15. Annual Review of Signifor<sup>®</sup> LAR (Pasireotide) – See Appendix N**

- A. Current Prior Authorization Criteria
- B. Utilization of Signifor<sup>®</sup> LAR (Pasireotide)
- C. Prior Authorization of Signifor<sup>®</sup> LAR (Pasireotide)
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

**16. Industry News and Updates – See Appendix O**

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

**17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P**

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**18. Future Business\* (Upcoming Product and Class Reviews)**

- A. Skin Cancer Medications
- B. Targeted Immunomodulator Agents
- C. Inrebic<sup>®</sup> (Fedratinib)
- D. Elzonris<sup>®</sup> (Tagraxofusp-erzs)
- E. Constipation and Diarrhea Medications
- F. Antidepressants
- G. Atopic Dermatitis Medications
- H. Antiviral Medications
- I. Anticoagulants and Platelet Aggregation Inhibitors

*\*Future business subject to change.*

**19. Adjournment**